Skip to main content
Top
Published in:

09-05-2024 | Non-Hodgkin Lymphoma | REVIEW ARTICLE

The association between primary Sjogren’s syndrome and non-Hodgkin’s lymphoma: a systematic review and meta-analysis of cohort studies

Authors: Narges Ansari, Mansour Salesi

Published in: Clinical Rheumatology | Issue 7/2024

Login to get access

Abstract

Primary Sjögren’s syndrome (pSS), a chronic autoimmune condition, has been associated with an increased risk of several cancers. This study aims to delve into the relationship between pSS and the potential development of non-Hodgkin’s lymphoma (NHL) utilizing an in-depth systematic review and meta-analysis approach. To thoroughly explore the topic, we conducted a thorough examination of the literature, drawing from reputable databases such as ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar. Our data collection spanned until February 8, 2024, with no time limitation. Data were analyzed with Stata 14 software at a significance threshold of p < 0.05. We examined 15 cohort studies encompassing a total of 50,308 individuals from 1997 to 2023. The findings revealed a substantial link between pSS and the risk of NHL, evident across all demographics. Specifically, the standardized incidence ratio (SIR) was generally 8.78 (95% CI 5.51, 13.99), with similar trends observed in both men (SIR, 6.29; 95% CI 1.93, 20.51) and women (SIR, 9.60; 95% CI 5.89, 15.63). Additionally, the SIR (10.50 (95% CI 7, 15.75)), HR (2.82 (95% CI 1.28, 6.18)), and OR (10.50 (95% CI 3.04, 36.28)) indices further supported this association. Furthermore, the risk of non-NHL associated with pSS was noticeable across different age groups of 40–49 years (SIR, 30.13; 95% CI 14.62, 62.08), 50–59 years (SIR, 9.12; 95% CI 5.13, 16.19), and 60–69 years (SIR, 9; 95% CI 4.68, 17.32). pSS substantively augments the likelihood of NHL manifestation. It notably impacts females and those in earlier stages of adulthood with more acuity than males and older cohorts.
Appendix
Available only for authorised users
Footnotes
1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
 
2
International prospective register of systematic reviews.
 
3
Medical Subject Headings.
 
Literature
1.
go back to reference Duan W, Jiang F, Ouyang S, Yin W, Zeng Q, Yang H (2023) Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study. Front Neurol 14:1212868PubMedPubMedCentralCrossRef Duan W, Jiang F, Ouyang S, Yin W, Zeng Q, Yang H (2023) Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study. Front Neurol 14:1212868PubMedPubMedCentralCrossRef
2.
go back to reference Luo W, Tian L, Tan B, Shen Z, Xiao M, Wu S et al (2022) Update: innate lymphoid cells in inflammatory bowel disease. Dig Dis Sci 67(1):56–66PubMedCrossRef Luo W, Tian L, Tan B, Shen Z, Xiao M, Wu S et al (2022) Update: innate lymphoid cells in inflammatory bowel disease. Dig Dis Sci 67(1):56–66PubMedCrossRef
3.
go back to reference Rajaei E, Jalali MT, Pezeshki SMS, Rezaeeyan H, Maniati M, Elyasi M et al (2020) Dose HLA-B5, 7, 8, 27, and 51 antigens associated to behcet’s disease? A study in Southwestern Iran. Curr Rheumatol Rev 16(2):120–124PubMedCrossRef Rajaei E, Jalali MT, Pezeshki SMS, Rezaeeyan H, Maniati M, Elyasi M et al (2020) Dose HLA-B5, 7, 8, 27, and 51 antigens associated to behcet’s disease? A study in Southwestern Iran. Curr Rheumatol Rev 16(2):120–124PubMedCrossRef
4.
go back to reference Rajaei E, Shahbazian N, Rezaeeyan H, Mohammadi AK, Hesam S, Zayeri ZD (2019) The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. Clin Rheumatol 38:3211–3215PubMedCrossRef Rajaei E, Shahbazian N, Rezaeeyan H, Mohammadi AK, Hesam S, Zayeri ZD (2019) The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. Clin Rheumatol 38:3211–3215PubMedCrossRef
5.
go back to reference Narvaez J, Sanchez-Fernandez SA, Seoane-Mato D, Diaz-Gonzalez F, Bustabad S (2020) Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Sci Rep 10(1):10627PubMedPubMedCentralCrossRef Narvaez J, Sanchez-Fernandez SA, Seoane-Mato D, Diaz-Gonzalez F, Bustabad S (2020) Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Sci Rep 10(1):10627PubMedPubMedCentralCrossRef
6.
go back to reference Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X et al (2016) Sjögren syndrome. Nat Rev Dis Primers 2(1):1–20CrossRef Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X et al (2016) Sjögren syndrome. Nat Rev Dis Primers 2(1):1–20CrossRef
7.
go back to reference Leone M, Alunno A, Cafaro G, Valentini V, Marcucci E, Bartoloni E et al (2017) The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo 69(3):93–100PubMedCrossRef Leone M, Alunno A, Cafaro G, Valentini V, Marcucci E, Bartoloni E et al (2017) The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo 69(3):93–100PubMedCrossRef
8.
go back to reference Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 9(9):544–556PubMedCrossRef Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol 9(9):544–556PubMedCrossRef
9.
go back to reference Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983–1989PubMedCrossRef Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983–1989PubMedCrossRef
10.
12.
go back to reference Theander E, Manthorpe R, Jacobsson L (2004) Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 50(4):1262–1269PubMedCrossRef Theander E, Manthorpe R, Jacobsson L (2004) Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 50(4):1262–1269PubMedCrossRef
13.
go back to reference Retamozo S, Gheitasi H, Quartuccio L, Kostov B, Corazza L, Bové A et al (2016) Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford) 55(8):1443–1451PubMedCrossRef Retamozo S, Gheitasi H, Quartuccio L, Kostov B, Corazza L, Bové A et al (2016) Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford) 55(8):1443–1451PubMedCrossRef
14.
go back to reference Shahjahani M, Abroun A, Saki N, Bagher Mohammadi SM, Rezaeeyan H (2020) STAT5: from pathogenesis mechanism to therapeutic approach in acute leukemia. Lab Med 51(4):345–351PubMedCrossRef Shahjahani M, Abroun A, Saki N, Bagher Mohammadi SM, Rezaeeyan H (2020) STAT5: from pathogenesis mechanism to therapeutic approach in acute leukemia. Lab Med 51(4):345–351PubMedCrossRef
15.
go back to reference Zintzaras E, Voulgarelis M, Moutsopoulos H (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344PubMedCrossRef Zintzaras E, Voulgarelis M, Moutsopoulos H (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344PubMedCrossRef
16.
go back to reference Pan L, Feng F, Wu J, Fan S, Han J, Wang S et al (2022) Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res 181:106270PubMedCrossRef Pan L, Feng F, Wu J, Fan S, Han J, Wang S et al (2022) Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res 181:106270PubMedCrossRef
17.
go back to reference Tabatabaee S, Bahrami F, Janahmadi M (2021) The critical modulatory role of spiny stellate cells in seizure onset based on dynamic analysis of a neural mass model. Front Neurosci 15:743720PubMedPubMedCentralCrossRef Tabatabaee S, Bahrami F, Janahmadi M (2021) The critical modulatory role of spiny stellate cells in seizure onset based on dynamic analysis of a neural mass model. Front Neurosci 15:743720PubMedPubMedCentralCrossRef
18.
go back to reference Shen W, Pei P, Zhang C, Li J, Han X, Liu T et al (2023) A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano 17(23):23998–24011PubMedCrossRef Shen W, Pei P, Zhang C, Li J, Han X, Liu T et al (2023) A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano 17(23):23998–24011PubMedCrossRef
19.
go back to reference Tian Z, Zhang Y, Zheng Z, Zhang M, Zhang T, Jin J et al (2022) Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. Cell host & microbe 30(10):1450–63.e8CrossRef Tian Z, Zhang Y, Zheng Z, Zhang M, Zhang T, Jin J et al (2022) Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. Cell host & microbe 30(10):1450–63.e8CrossRef
20.
go back to reference Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P et al (2024) The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma. Heliyon 10(1):e23915PubMedCrossRef Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P et al (2024) The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma. Heliyon 10(1):e23915PubMedCrossRef
22.
go back to reference Gan Y, Li L, Zhang L, Yan S, Gao C, Hu S et al (2018) Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. Carcinogenesis 39(2):87–97PubMedCrossRef Gan Y, Li L, Zhang L, Yan S, Gao C, Hu S et al (2018) Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. Carcinogenesis 39(2):87–97PubMedCrossRef
23.
24.
go back to reference Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W et al (2023) KRT17 promotes T-lymphocyte infiltration through the YTHDF2–CXCL10 axis in colorectal cancer. Cancer Immunol Res 11(7):875–894PubMedPubMedCentralCrossRef Liang W, Liu H, Zeng Z, Liang Z, Xie H, Li W et al (2023) KRT17 promotes T-lymphocyte infiltration through the YTHDF2–CXCL10 axis in colorectal cancer. Cancer Immunol Res 11(7):875–894PubMedPubMedCentralCrossRef
25.
go back to reference Aslan B, Öğüt T, Erbasan F, Dilbil M, Çelik E, Terzioğlu M et al (2022) The risk of cancer in patients with primary sjögrensyndrome; a single-center study from Turkey. Turk J Med Sci 52(3):587–595PubMedCrossRef Aslan B, Öğüt T, Erbasan F, Dilbil M, Çelik E, Terzioğlu M et al (2022) The risk of cancer in patients with primary sjögrensyndrome; a single-center study from Turkey. Turk J Med Sci 52(3):587–595PubMedCrossRef
26.
go back to reference Goulabchand R, Malafaye N, Jacot W, Viel P, Morel J, Lukas C et al (2021) Cancer incidence in primary sjögren’s syndrome: data from the French hospitalization database. Autoimmun Rev 20(12):102987PubMedCrossRef Goulabchand R, Malafaye N, Jacot W, Viel P, Morel J, Lukas C et al (2021) Cancer incidence in primary sjögren’s syndrome: data from the French hospitalization database. Autoimmun Rev 20(12):102987PubMedCrossRef
27.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://doi.org/10.1186/2046-4053-4-1 Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://​doi.​org/​10.​1186/​2046-4053-4-1
28.
go back to reference Peterson J, Welch V, Losos M, Tugwell PJOOHRI (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hosp Res Inst 2(1):1–12 Peterson J, Welch V, Losos M, Tugwell PJOOHRI (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hosp Res Inst 2(1):1–12
29.
go back to reference Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
30.
go back to reference Kang J, Kim H, Kim J, Choi S, Jung S, Jang E et al (2020) Risk of malignancy in Korean patients with primary sjögren’s syndrome. Int J Rheum Dis 23(9):1240–1247PubMedCrossRef Kang J, Kim H, Kim J, Choi S, Jung S, Jang E et al (2020) Risk of malignancy in Korean patients with primary sjögren’s syndrome. Int J Rheum Dis 23(9):1240–1247PubMedCrossRef
31.
go back to reference Mayer M, Martinic M, Reihl-Crnogaj M, Anic B (2023) The risk of developing non-Hodgkin lymphoma and the mortality rate in primary sjögren’s syndrome: a single-centre, retrospective cohort study. Rheumatol Int 43(11):2031–2036PubMedCrossRef Mayer M, Martinic M, Reihl-Crnogaj M, Anic B (2023) The risk of developing non-Hodgkin lymphoma and the mortality rate in primary sjögren’s syndrome: a single-centre, retrospective cohort study. Rheumatol Int 43(11):2031–2036PubMedCrossRef
32.
go back to reference Isik O, Yazici A, Cefle A (2022) The relationship between malignancy and primary sjogren’s syndrome; single center results. Acta Medica Nicomedia 5(2):49–55CrossRef Isik O, Yazici A, Cefle A (2022) The relationship between malignancy and primary sjogren’s syndrome; single center results. Acta Medica Nicomedia 5(2):49–55CrossRef
33.
go back to reference Wang L, Wang W, Lin C, Lin S, Shieh C (2020) Bidirectional relationship between primary sjögren syndrome and non-Hodgkin lymphoma: a nationwide Taiwanese population-based study. J Rheumatol 47(9):1374–1378PubMedCrossRef Wang L, Wang W, Lin C, Lin S, Shieh C (2020) Bidirectional relationship between primary sjögren syndrome and non-Hodgkin lymphoma: a nationwide Taiwanese population-based study. J Rheumatol 47(9):1374–1378PubMedCrossRef
34.
go back to reference Ahn J, Hwang J, Seo G (2020) Risk of non-Hodgkin’s lymphoma and thyroid cancer in primary Sjögren’s syndrome measured using the Korean Health Insurance Claims Database. Clin Exp Rheumatol 38:40–6PubMed Ahn J, Hwang J, Seo G (2020) Risk of non-Hodgkin’s lymphoma and thyroid cancer in primary Sjögren’s syndrome measured using the Korean Health Insurance Claims Database. Clin Exp Rheumatol 38:40–6PubMed
35.
go back to reference Brom M, Moyano S, Gandino I, Scolnik M, Soriano E (2019) Incidence of cancer in a cohort of patients with primary sjögren syndrome in Argentina. Rheumatol Int 39(10):1697–1702PubMedCrossRef Brom M, Moyano S, Gandino I, Scolnik M, Soriano E (2019) Incidence of cancer in a cohort of patients with primary sjögren syndrome in Argentina. Rheumatol Int 39(10):1697–1702PubMedCrossRef
36.
go back to reference Brito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón F et al (2017) Characterization and risk estimate of cancer in patients with primary sjögren syndrome. J Hematol Oncol 10(1):90PubMedPubMedCentralCrossRef Brito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón F et al (2017) Characterization and risk estimate of cancer in patients with primary sjögren syndrome. J Hematol Oncol 10(1):90PubMedPubMedCentralCrossRef
37.
go back to reference Chiu Y, Chung C, Lin K, Lin C, Chen J, Chen H et al (2017) Predictable biomarkers of developing lymphoma in patients with sjögren syndrome: a nationwide population-based cohort study. Oncotarget 8(30):50098–50108PubMedPubMedCentralCrossRef Chiu Y, Chung C, Lin K, Lin C, Chen J, Chen H et al (2017) Predictable biomarkers of developing lymphoma in patients with sjögren syndrome: a nationwide population-based cohort study. Oncotarget 8(30):50098–50108PubMedPubMedCentralCrossRef
38.
go back to reference Abrol E, González-Pulido C, Praena-Fernández J, Isenberg D (2014) A retrospective study of long-term outcomes in 152 patients with primary sjögren’s syndrome: 25-year experience. Clin Med 14(2):157–164CrossRef Abrol E, González-Pulido C, Praena-Fernández J, Isenberg D (2014) A retrospective study of long-term outcomes in 152 patients with primary sjögren’s syndrome: 25-year experience. Clin Med 14(2):157–164CrossRef
39.
go back to reference Johnsen S, Brun J, Gøransson L, Småstuen M, Johannesen T, Haldorsen K et al (2013) Risk of non-Hodgkin’s lymphoma in primary sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 65(5):816–821PubMedCrossRef Johnsen S, Brun J, Gøransson L, Småstuen M, Johannesen T, Haldorsen K et al (2013) Risk of non-Hodgkin’s lymphoma in primary sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 65(5):816–821PubMedCrossRef
40.
go back to reference Weng M, Huang Y, Liu M, Lu T (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary sjögren’s syndrome in Taiwan. Ann Rheum Dis 71(4):524–527PubMedCrossRef Weng M, Huang Y, Liu M, Lu T (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary sjögren’s syndrome in Taiwan. Ann Rheum Dis 71(4):524–527PubMedCrossRef
41.
go back to reference Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson L (2006) Lymphoma and other malignancies in primary sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6):796–803PubMedCrossRef Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson L (2006) Lymphoma and other malignancies in primary sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6):796–803PubMedCrossRef
42.
go back to reference Kauppi M, Pukkala E, Isomäki H (1997) Elevated incidence of hematologic malignancies in patients with sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8(2):201–204PubMedCrossRef Kauppi M, Pukkala E, Isomäki H (1997) Elevated incidence of hematologic malignancies in patients with sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8(2):201–204PubMedCrossRef
43.
go back to reference Liang Y, Yang Z, Qin B, Zhong R (2014) Primary sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73(6):1151–1156PubMedCrossRef Liang Y, Yang Z, Qin B, Zhong R (2014) Primary sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73(6):1151–1156PubMedCrossRef
44.
go back to reference Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y et al (2022) Primary sjögren’s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 5:103084CrossRef Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y et al (2022) Primary sjögren’s syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis. Autoimmun Rev 5:103084CrossRef
45.
go back to reference Ekström Smedby K, Vajdic C, Falster M, Engels E, Martínez-Maza O, Turner J et al (2008) Autoimmune disorders and risk of non-hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood 111(8):4029–4038PubMedPubMedCentralCrossRef Ekström Smedby K, Vajdic C, Falster M, Engels E, Martínez-Maza O, Turner J et al (2008) Autoimmune disorders and risk of non-hodgkin lymphoma subtypes: a pooled analysis within the interlymph consortium. Blood 111(8):4029–4038PubMedPubMedCentralCrossRef
46.
go back to reference Ekström Smedby K, Hjalgrim H, Askling J, Chang E, Gregersen H, Porwit-MacDonald A et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-hodgkin lymphoma by subtype. J Natl Cancer Inst 98(1):51–60CrossRef Ekström Smedby K, Hjalgrim H, Askling J, Chang E, Gregersen H, Porwit-MacDonald A et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-hodgkin lymphoma by subtype. J Natl Cancer Inst 98(1):51–60CrossRef
47.
go back to reference Lazarus M, Robinson D, Mak V, Møller H, Isenberg D (2006) Incidence of cancer in a cohort of patients with primary sjogren’s syndrome. Rheumatology (Oxford) 45(8):1012–1015PubMedCrossRef Lazarus M, Robinson D, Mak V, Møller H, Isenberg D (2006) Incidence of cancer in a cohort of patients with primary sjogren’s syndrome. Rheumatology (Oxford) 45(8):1012–1015PubMedCrossRef
48.
go back to reference Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J et al (2010) Incidence of malignancy in primary sjögren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49(3):571–577PubMedCrossRef Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J et al (2010) Incidence of malignancy in primary sjögren’s syndrome in a Chinese cohort. Rheumatology (Oxford) 49(3):571–577PubMedCrossRef
49.
go back to reference Shi X, Wallach J, Ma X, Rogne T (2024) Autoimmune diseases and risk of non-Hodgkin lymphoma: a Mendelian randomisation study. medRxiv 73(1):17 Shi X, Wallach J, Ma X, Rogne T (2024) Autoimmune diseases and risk of non-Hodgkin lymphoma: a Mendelian randomisation study. medRxiv 73(1):17
Metadata
Title
The association between primary Sjogren’s syndrome and non-Hodgkin’s lymphoma: a systematic review and meta-analysis of cohort studies
Authors
Narges Ansari
Mansour Salesi
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 7/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06993-6

Other articles of this Issue 7/2024

Clinical Rheumatology 7/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare